ÎåÐÇÌåÓýÖ±²¥ to Participate in Upcoming Virtual Healthcare Conferences

REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- ÎåÐÇÌåÓýÖ±²¥ (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in three upcoming virtual investment conferences.

  • The UBS Global Healthcare Virtual Conference – May 24, 2021 at 11:00 a.m. ET, corporate presentation; a live webcast of the conference presentation will be available in the Investor Relations section of the Company’s website, . Replays of the webcast will be archived for 30 days following the event.
  • The SynBioBeta Synthetic Biology Biopharma Conference – May 26, 2021 at 11:10 a.m. ET, Exponential Change: What Should We Expect for Biopharma 2025 Panel
  • The Benchmark Company Healthcare House Call Conference – May 26, 2021, management will attend and host 1x1 investor meetings

About ÎåÐÇÌåÓýÖ±²¥
ÎåÐÇÌåÓýÖ±²¥ is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance enzymes and novel biotherapeutics. ÎåÐÇÌåÓýÖ±²¥ enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; in the creation of the next generation of life science tools; and as gene therapy and biologic therapeutics. The Company’s unique performance enzymes drive improvements such as: reduced energy usage, waste generation and capital requirements; higher yields; higher fidelity diagnostics; and more efficacious therapeutics. ÎåÐÇÌåÓýÖ±²¥ enzymes enable the promise of synthetic biology to improve the health of people and the planet. For more information, visit .

Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding ÎåÐÇÌåÓýÖ±²¥, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause ÎåÐÇÌåÓýÖ±²¥â€™ future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. ÎåÐÇÌåÓýÖ±²¥ undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ÎåÐÇÌåÓýÖ±²¥â€™ business in general, please refer to ÎåÐÇÌåÓýÖ±²¥â€™ prospectus supplement to be filed with the SEC, including the documents incorporated by reference therein, which include ÎåÐÇÌåÓýÖ±²¥â€™ Annual Report on Form 10-K filed with the SEC on March 1, 2021, ÎåÐÇÌåÓýÖ±²¥â€™ Quarterly Report on Form 10-Q filed with thee SEC on May 7, 2021, and ÎåÐÇÌåÓýÖ±²¥â€™ other periodic reports filed with the SEC.

Investor Relations Contact:
Argot Partners
Stephanie Marks/Carrie McKim
(212) 600-1902
ÎåÐÇÌåÓýÖ±²¥@argotpartners.com


Source: ÎåÐÇÌåÓýÖ±²¥